N-[2-(3,6-dihydropyridin-1(2H)-yl)ethyl]-N-methylamine | 847556-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-(3,6-dihydropyridin-1(2H)-yl)ethyl]-N-methylamine
• 英文别名: 2-(3,6-dihydropyridin-1(2H)-yl)-N-methylethanamine；2-(3,6-dihydro-2H-pyridin-1-yl)-N-methylethanamine
• CAS: 847556-18-7
• 化学式: C₈H₁₆N₂
• 分子量: 140.228
• InChiKey: DJLZKCPEXBVIJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,1-dimethylethyl N-[2-(3,6-dihydropyridin-1(2H)-yl)ethyl]carbamate 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 6.17h， 以42%的产率得到N-[2-(3,6-dihydropyridin-1(2H)-yl)ethyl]-N-methylamine
  参考文献：
  名称：

  EP1661898

  摘要：

  公开号：

文献信息

• Bicyclic piperazine compound and use thereof
  申请人：Fukatsu Kohji

  公开号：US20070072865A1

  公开（公告）日：2007-03-29

  The present invention provides a compound represented by the formula: wherein R 1 is an acyl group, R 2 is a hydrocarbon group which may be substituted or the like, R 3 is a hydrocarbon group which may be substituted or the like, R 4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.

  本发明提供一种化合物，其化学式为：其中，R1是酰基，R2是烃基，可以被取代或类似物，R3是烃基，可以被取代或类似物，R4是烃基，可以被取代或类似物，n为0至4，X为氧原子、硫原子或类似物或其盐。本发明还提供一种具有TGR23拮抗活性的化合物，因此可用于预防和治疗癌症。
• Bicyclic piperazine compound having TGR23 antagonistic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07795267B2

  公开（公告）日：2010-09-14

  The present invention provides a compound represented by the formula: wherein R1 is —(C═O)—NR7R8 or —(C═O)—OR6, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.

  本发明提供了一种化合物，其表示为以下公式：其中R1为—（C═O）—NR7R8或—（C═O）—OR6，R2为可取代或类似的烃基，R3为可取代或类似的烃基，R4为可取代或类似的烃基，n为0至4，X为氧原子或其盐。本发明还提供了一种具有TGR23拮抗活性的化合物，因此可用于预防和治疗癌症。
• C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
  申请人：Sugimoto Tomohiro

  公开号：US20140046043A1

  公开（公告）日：2014-02-13

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种大环内酯化合物，化学式为（I），对红霉素耐药的细菌有效（例如，耐药的肺炎球菌，链球菌和支原体）。
• C-4″ position substituted macrolide derivative
  申请人：Sugimoto Tomohiro

  公开号：US09139609B2

  公开（公告）日：2015-09-22

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种大环内酯化合物，化学式为(I)，对红霉素耐药细菌（例如，耐药性肺炎球菌，链球菌和支原体）具有有效性。
• Amino Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239894A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R 12 or R 13 on the A group is an amino substituent (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了公式I或其药学上可接受的盐或组合物所组成的抑制补体因子D的化合物、使用方法和制备过程，其中A组上的R12或R13是氨基取代基（R32）。所述抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。